A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease

被引:0
|
作者
Tarrass, F. [1 ]
Yazidi, A. [1 ]
Sif, H. [1 ]
Zamd, M. [1 ]
Benghanem, M. G. [1 ]
Ramdani, B. [1 ]
机构
[1] Ibn Rochd Univ Hosp Ctr, Dept Nephrol & Dialysis, Casablanca, Morocco
关键词
secondary hyperparathyroidism; alfacalcidol; end-stage renal disease; hemodialysis;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Secondary hyperparathyroidism, a major clinical problem in patients with chronic renal failure, develops in response to phosphate retention and impaired calcitriol [1,25-dihydroxyvitamin D-3] synthesis. Vitamin D therapy, particularly alfacalcidol [1 alpha-hydroxyvitamin D-3], has been shown to be effective in the treatment of secondary hyperparathyroidism. The aim of this study was to compare the effect of a 12-week course of continuous versus intermittent oral alfacalcidol therapy on parathyroid hormone suppression. Patients and methods: 34 patients were selected and randomly divided into 2 groups to receive either intermittent or continuous oral alfacalcidol. Baseline data were obtained on serum calcium, phosphorus, alkaline phosphatase and PTH. All but the PTH were monitored monthly. PTH levels were measured again until the end of the protocol. The intervention was 2 mu g of alfacalcidol given after each dialysis session (intermittent group) or 1 mu g given 6 days/week (continuous group). Results: Serum calcium and phosphorus showed a tendency to increase from baseline levels in both groups. Mean PTH levels for both groups showed a progressive reduction over time during the study period. This decrement showed no significant difference with regard to the schedule of alfacalcidol administration when comparing the 2 groups. There also was no difference in the incidence of side effects hypercalcemia and hyperphosphatemia - between the intermittent and continuous intervention. Conclusion: Feedback regulation of PTH with oral alfacalcidol therapy is efficient in the treatment of hyperparathyroidism. However, intermittent and continuous oral administration are equally effective in suppressing an elevated PTH level in hemodialysis patients, with similar safety margins.
引用
收藏
页码:415 / 418
页数:4
相关论文
共 50 条
  • [1] ORAL CALCITRIOL VERSUS ORAL ALFACALCIDOL FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS RECEIVING HEMODIALYSIS: A RANDOMIZED, CROSSOVER TRIAL
    Moe, Samantha
    Wazny, Lori D.
    Martin, Janet E.
    JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2008, 15 (01): : E36 - E43
  • [2] Pulse versus daily oral Alfacalcidol treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized controlled trial
    Sawalmeh, Osama
    Moala, Shaheed
    Hamdan, Zakaria
    Masri, Huda
    Ayoub, Khubaib
    Khazneh, Emad
    Shraim, Mujahed
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2018, 11 : 25 - 32
  • [3] Empowerment of patients with end-stage renal disease - a randomized controlled trial
    Tsay, SL
    Hung, LO
    INTERNATIONAL JOURNAL OF NURSING STUDIES, 2004, 41 (01) : 59 - 65
  • [4] Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease
    Muscheites, Jutta
    Wigger, Marianne
    Drueckler, Erdmute
    Fischer, Dagmar-Christiane
    Kundt, Guenther
    Haffner, Dieter
    PEDIATRIC NEPHROLOGY, 2008, 23 (10) : 1823 - 1829
  • [5] Smoking and hyperparathyroidism in patients with end-stage renal disease (ESRD)
    Tripepi, Giovanni
    Mattace-Raso, Francesco
    Pizzini, Patrizia
    Cutrupi, Sebastiano
    Witteman, Jacqueline
    Zoccali, Carmine
    Mallamaci, Francesca
    JOURNAL OF NEPHROLOGY, 2012, 25 (01) : 75 - 83
  • [6] Utilization of parathyroidectomy for secondary hyperparathyroidism in end-stage renal disease
    Konstantinidis, Ioannis
    Nadkarni, Girish
    Divino, Celia M.
    Lapsia, Vijay
    CLINICAL KIDNEY JOURNAL, 2013, 6 (03) : 277 - 282
  • [7] Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease
    Jutta Muscheites
    Marianne Wigger
    Erdmute Drueckler
    Dagmar-Christiane Fischer
    Guenther Kundt
    Dieter Haffner
    Pediatric Nephrology, 2008, 23 : 1823 - 1829
  • [8] Pancytopenia in Secondary Hyperparathyroidism Due to End-Stage Renal Disease
    Sharma, Sharan Prakash
    Siu, Karleung
    AMERICAN JOURNAL OF MEDICINE, 2013, 126 (12): : E11 - E12
  • [9] Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease
    Muscheites, J.
    Wigger, M.
    Drueckler, E.
    Fischer, D. C.
    Kundt, G.
    Haffner, D.
    PEDIATRIC NEPHROLOGY, 2008, 23 (09) : 1603 - 1603
  • [10] Minimodeling in secondary hyperparathyroidism in patients with end-stage renal disease
    Yajima, A
    Ogawa, Y
    Tominaga, Y
    Urena, P
    Inou, T
    Otsubo, O
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V80 - V80